Precision Oncology in AML: Molecular Insights, Maintenance Strategies, and Emerging Therapies : Episode 6
Clinical Scenario: TP53- Mutant AML
Panelists discuss the clinical scenario of TP53-mutant acute myeloid lymphoma (AML), focusing on treatment approaches and key challenges in managing this high-risk patient group.
Video Player is loading.
EP: 1.All Oral Regimen of Oral Azacitidine and Venetoclax for Newly Diagnosed and Relapsed/Refractory AML
EP: 2.AUGMENT-101 Updated Results and Longer Follow-Up of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
EP: 3.Debate: What Is the Best Posttransplant Follow-Up - Maintenance vs Close Monitoring With Laboratory Testing
EP: 4.Debate: Treating Patients With Relapsed/Recurrent AML - MENIN Inhibitors vs Standard of Care
EP: 5.Clinical Scenario: Newly Diagnosed AML With an NPM1 Mutation
Now Viewing
EP: 6.Clinical Scenario: TP53- Mutant AML
Recent Videos
Navigating Treatment Choices in R/R FL: Patient Values and Shared Decision-Making
Assessing CAR T and Bispecifics for R/R FL: Identifying the Right Candidates & Factoring in CD20 and CD19 Negativity or Positivity
Managing Epithelioid Sarcoma: Follow-Up Strategies and Treatment Decisions for Stable Disease vs Progression
Navigating Frontline Therapy in Epithelioid Sarcoma: Key Clinical Considerations and Shared Decision-Making
Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
Institutional Implementation: Setting Up Tarlatamab Administration
Clinician Experiences: COCOON Regimen vs Traditional SoC AE Management
Initial Reactions to COCOON Study’s Dermatologic/Nail AE Reductions
Choosing Between Tazemetostat and Zanubrutinib+Obinutuzumab: Key Factors & Patient Conversations
Research Considerations for ctDNA Testing in Colorectal Cancer
Related Content
